Display options
Cite
Yoshimoto T, Mizoguchi I, Katagiri S, et al. Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse. Oncoimmunology. 2014;3:e28861doi: 10.4161/onci.28861.
Yoshimoto, T., Mizoguchi, I., Katagiri, S., Tauchi, T., Furusawa, J. I., Chiba, Y., Mizuguchi, J., Ohyashiki, J. H., & Ohyashiki, K. (2014). Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse. Oncoimmunology, 3e28861. https://doi.org/10.4161/onci.28861
Yoshimoto, Takayuki, et al. "Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse." Oncoimmunology vol. 3 (2014): e28861. doi: https://doi.org/10.4161/onci.28861
Yoshimoto T, Mizoguchi I, Katagiri S, Tauchi T, Furusawa JI, Chiba Y, Mizuguchi J, Ohyashiki JH, Ohyashiki K. Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse. Oncoimmunology. 2014 May 14;3:e28861. doi: 10.4161/onci.28861. eCollection 2014. PMID: 25057448; PMCID: PMC4091524.
Copy Download .nbib Format: NLM
Share it on

Oncoimmunology. 2014 May 14;3:e28861. doi: 10.4161/onci.28861. eCollection 2014.

Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse.

Oncoimmunology

Takayuki Yoshimoto, Izuru Mizoguchi, Seiichiro Katagiri, Tetsuzo Tauchi, Jun-Ichi Furusawa, Yukino Chiba, Junichiro Mizuguchi, Junko H Ohyashiki, Kazuma Ohyashiki

Affiliations

  1. Department of Immunoregulation; Institute of Medical Science; Tokyo Medical University; Tokyo, Japan.
  2. Department of Hematology; Tokyo Medical University; Tokyo, Japan.
  3. Department of Immunoregulation; Institute of Medical Science; Tokyo Medical University; Tokyo, Japan ; Department of Immunology; Tokyo Medical University; Tokyo, Japan.
  4. Department of Immunology; Tokyo Medical University; Tokyo, Japan.
  5. Department of Molecular Oncology; Institute of Medical Science; Tokyo Medical University; Tokyo, Japan.

PMID: 25057448 PMCID: PMC4091524 DOI: 10.4161/onci.28861

Abstract

Tyrosine kinase inhibitors have dramatically improved the treatment of chronic myeloid leukemia. Recent evidence revealed that some patients with chronic myeloid leukemia can stop imatinib without relapse after achieving a complete molecular response. This review discusses the possible predictive markers to identify these patients who can stop imatinib without relapse.

Keywords: NK cells; chronic myeloid leukemia; cytotoxic T lymphocytes; imatinib; immunosurvelliance; predictive marker

References

  1. J Clin Oncol. 2010 Mar 10;28(8):1429-35 - PubMed
  2. PLoS One. 2011;6(11):e27639 - PubMed
  3. Lancet Oncol. 2010 Nov;11(11):1029-35 - PubMed
  4. Blood. 2000 Nov 15;96(10):3343-56 - PubMed
  5. Br J Haematol. 2012 Apr;157(2):254-6 - PubMed
  6. Leukemia. 2010 Oct;24(10):1719-24 - PubMed
  7. Nat Med. 1996 May;2(5):561-6 - PubMed
  8. PLoS One. 2011;6(8):e23022 - PubMed
  9. Cancer Sci. 2013 Sep;104(9):1146-53 - PubMed
  10. Haematologica. 2012 Jun;97(6):903-6 - PubMed

Publication Types